AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

NCT00089674 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1468

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: AMG 162
DRUG: Placebo

Sponsor

Amgen